AUTHOR=Kozak Rouba , Kiss Tamás , Dlugolenski Keith , Johnson David E. , Gorczyca Roxanne R. , Kuszpit Kyle , Harvey Brian D. , Stolyar Polina , Sukoff Rizzo Stacey J. , Hoffmann William E. , Volfson Dmitri , Hajós Mihaly , Davoren Jennifer E. , Abbott Amanda L. , Williams Graham V. , Castner Stacy A. , Gray David L. TITLE=Characterization of PF-6142, a Novel, Non-Catecholamine Dopamine Receptor D1 Agonist, in Murine and Nonhuman Primate Models of Dopaminergic Activation JOURNAL=Frontiers in Pharmacology VOLUME=11 YEAR=2020 URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.01005 DOI=10.3389/fphar.2020.01005 ISSN=1663-9812 ABSTRACT=
Selective activation of dopamine D1 receptors remains a promising pro-cognitive therapeutic strategy awaiting robust clinical investigation. PF-6142 is a key example from a recently disclosed novel series of non-catechol agonists and partial agonists of the dopamine D1/5 receptors (D1R) that exhibit pharmacokinetic (PK) properties suitable for oral delivery. Given their reported potential for functionally biased signaling compared to known catechol-based selective agonists, and the promising rodent PK profile of PF-6142, we utilized relevant